EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Cost-effectiveness analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at low risk of surgical mortality in Sweden

Konrad Nilsson, Stefan James, Oskar Angerås, Jenny Backes, Henrik Bjursten, Pascal Candolfi, Mattias Götberg, Henrik Hagström, Chiara Malmberg, Niels Erik Nielsen, Archita Sarmah, Magnus Settergren und 1 weitere

Upsala Journal of Medical Sciences · 2024

DOI: 10.48101/ujms.v129.10741 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Upsala Journal of Medical Sciences, 2024. Verfasst von Konrad Nilsson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Cost-Benefit Analysis, Quality-Adjusted Life Years. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transcatheter aortic valve implantation (TAVI) has shown similar or improved clinical outcomes compared with surgical aortic valve replacement (SAVR) in patients with symptomatic severe aortic stenosis at low risk for surgical mortality. This cost-utility analysis compared TAVI with SAPIEN 3 versus SAVR in symptomatic severe aortic stenosis patients at low risk of surgical mortality from the perspective of the Swedish healthcare system.

Methods

A published, two-stage, Markov-based cost-utility model that captured clinical outcomes from the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated according to Recommended Therapies (SWEDEHEART) registry (2018–2020) was adapted from the perspective of the Swedish healthcare system using local general population mortality, utility and costs data. The model had a lifetime horizon. Model outputs included changes in direct healthcare costs and health-related quality of life from using TAVI as compared with SAVR.

Results

TAVI with SAPIEN 3 resulted in lifetime costs per patient of 940,541 Swedish krona (SEK) and lifetime quality-adjusted life years (QALYs) per patient of 7.16, whilst SAVR resulted in lifetime costs and QALYs per patient of 821,380 SEK and 6.81 QALYs, respectively. Compared with SAVR, TAVI offered an incremental improvement of +0.35 QALY per patient at an increased cost of +119,161 SEK per patient over a lifetime horizon, resulting in an incremental cost-effectiveness ratio of 343,918 SEK per QALY gained.

Conclusion

TAVI with SAPIEN 3 is a cost-effective option versus SAVR for patients with symptomatic severe aortic stenosis at low risk for surgical mortality treated in the Swedish healthcare setting. These findings may inform policy decisions in Sweden for the management of this patient group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic Valve StenosisCost-Benefit AnalysisQuality-Adjusted Life YearsHumansSwedenMaleFemaleAgedQuality of LifeAged, 80 and overHealth Care CostsHeart Valve Prosthesis ImplantationAortic ValveMarkov ChainsTreatment OutcomeCost-Effectiveness Analysis

Stichwörter der Autor:innen

Transcatheter aortic valve implantationaortic stenosiscost-effectivenesslow risksurgical aortic valve replacement

Autor:innen und Institutionen

  • Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
  • Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University, Gothenburg, Sweden.
  • Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Cardiothoracic and Vascular Surgery, Örebro University Hospital, Örebro, Sweden.
  • Department of Cardiothoracic Surgery, Anaesthesia and Intensive Care, Lund University, Lund, Sweden.
  • Department of Cardiothoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden.

Zitieren

APA

Nilsson, K., James, S., Angerås, O., Backes, J., Bjursten, H., Candolfi, P., Götberg, M., Hagström, H., Malmberg, C., Nielsen, N. E., Sarmah, A., Settergren, M., & Bromilow, T. (2024). Cost-effectiveness analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at low risk of surgical mortality in Sweden. Upsala Journal of Medical Sciences. https://doi.org/10.48101/ujms.v129.10741

Vancouver

Nilsson K, James S, Angerås O, Backes J, Bjursten H, Candolfi P, et al. Cost-effectiveness analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at low risk of surgical mortality in Sweden. Upsala Journal of Medical Sciences. 2024. doi:10.48101/ujms.v129.10741

BibTeX
@article{Nilsson2024,
  author = {Nilsson, Konrad and James, Stefan and Angerås, Oskar and Backes, Jenny and Bjursten, Henrik and Candolfi, Pascal and Götberg, Mattias and Hagström, Henrik and Malmberg, Chiara and Nielsen, Niels Erik and Sarmah, Archita and Settergren, Magnus and Bromilow, Tom},
  title = {Cost-effectiveness analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at low risk of surgical mortality in Sweden},
  journal = {Upsala Journal of Medical Sciences},
  year = {2024},
  doi = {10.48101/ujms.v129.10741}
}
Kostenlos starten →